Bli medlem
Bli medlem

Du är här


BioInvent: BioInvent extends manufacturing services contract with major global pharmaceutical client; expects to generate approximately SEK 8 million in revenue

Lund, Sweden - 29 August 2016 - BioInvent International (OMXS: BINV)
announces that it has signed an extended contract for manufacturing
services with one of its current customers, a major global
pharmaceutical client. The extension covers services for one of the
products in the pharmaceutical company's development portfolio.

Michael Oredsson, President and CEO of BioInvent, said: "We are
pleased that we have been contracted to provide additional
manufacturing services to this major global pharmaceutical client.
The extension of our relationship reflects BioInvent's world-leading
expertise in antibody production based around our cGMP-certified
facilities, which meet EU and standards. This new agreement is
expected to generate about SEK 8 million in revenue, with the
majority occurring in 2016."

During the year BioInvent has strengthened its ability to
independently produce antibodies following the decision to invest in
a "Single Use Bioreactor". This will benefit the development of our
internal projects, and will also generate revenue from external
companies. BioInvent's production facility has the capacity to
produce antibodies, both for research purposes as for clinical trials
all the way through to Phase III.

To the editors:

About BioInvent
BioInvent International AB develops immune oncology drugs. With one of
the world's largest antibody libraries, and a unique, proprietary
discovery method, BioInvent can identify the optimal cellular targets
and antibodies for the treatment of various tumor types. BioInvent
has also considerable experience in and a facility for process
development and production of antibodies for clinical studies. This
makes it possible to develop proprietary drug projects, but also to
supply leading international pharmaceutical companies with effective
tools for their drug development. BioInvent currently has three
proprietary projects in or close to clinical development and
partnership agreements with seven global pharmaceutical and biotech
companies. More information is available at

For further information, please contact:
Michael Oredsson
President and CEO
+46 (0)46 286 85 67
+46 (0)707 16 89 30

Citigate Dewe Rogerson
David Dible/Marine Perrier
+44 (0)20 7282 1068

BioInvent International AB (publ)
Co. reg. No. 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50

The press release contains statements about the future, consisting of
subjective assumptions and forecasts for future scenarios.
Predictions for the future only apply as the date they are made and
are, by their very nature, in the same way as research and
development work in the biotech segment, associated with risk and
uncertainty. With this in mind, the actual outcome may deviate
significantly from the scenarios described in this press release.

This information is information that BioInvent International AB is
obliged to make public pursuant to the EU Market Abuse Regulation.
The information was submitted for publication, through the agency of
the contact person set out above, at 8.40 a.m. CET, on 29 August,


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.